|
Home
What is
Hepatitis
How is it
Transmitted
Long Term
Prognosis
Complications of
HCV
Liver
Biopsy
Treatment Info
(Interferon, Herbal, etc)
Lab Tests (PCR,
Genotype,etc.)
Nutrition
& Alternative Info
Patient
Information (Support Groups, Doctor Listing,
etc)
Related
Webpages
Transplant
Info
Site
Search
HCV
Webrings
My
guestbookbook
Site
Awards
FAQ &
Disclaimers
|
Dig Dis Sci 2000 Mar;45(3):565-74
Sustained viral response is rarely achieved in patients with high
viral load of HCV RNA by excessive interferon therapy.
Shiratori Y, Kato N, Yoshida H, Nakata R, Ihori M, Imazeki F,
Yokosuka O, Kawase T, Katamoto T, Unuma T, Nakamura A, Ikegami F,
Hirota K, Omata M Department of Internal Medicine
(Gastroenterology), University of Tokyo, Japan.
Adequate dosing of interferon (IFN) and its cost-effectiveness
for sustained virological response were evaluated in relation to
viral load and subtype.
Prospective analysis of IFN therapy on 326 patients with chronic
hepatitis C free from cirrhosis was performed using 9 or 6 million
unit (MU) of IFN for six months daily and/or three times a
week.
Sustained virological response was achieved in 50-94% of
patients with less than or = 2 x 10(4) copies/ml (competitive
RT-PCR) or less than 100 x 10(3) copies/ml (Amplicor monitor) of
HCV RNA by 468-1206 MU of IFN, but response was only 0-25% of the
patients with > or = 2 x 10(5.5) copies/ml (competitive RT-PCR)
or greater than 200 x 10(3) copies/ml (Amplicor monitor), even with
468-1206 MU of IFN.
A high sustained rate was demonstrated in patients with 100-200
x 10(3) copies/ml of HCV RNA by 901-1206 MU of IFN, in comparison
to that with less than or = 900 MU of IFN.
Multivariate analysis showed that IFN dose had a significant
value for the efficacy of IFN therapy in patients presenting
100-200 x 10(3) copies/ml of HCV RNA.
Cost efficacy analysis indicated that it cost approximately
$10,000, $26,000, and $50,000-227,000 for one person-viral
eradication in the patients with less than 100, 100-200, and
greater than 200 x 10(3) copies/ml, respectively.
High-dose IFN is only cost effective in patients with
intermediate viral loads, and IFN therapy could be recommended in
patients with less than 200 x 10(3) copies/ml of HCV RNA.
PMID: 10749334, UI: 20210905
Home | What is HCV | Transmission |
Future |
Complications |
Biopsy |
Treatment
| Lab |
Nutrition |
Patient |
Links | Transplant |
Webrings |
guestbookbook |
Awards |
FAQ
|
|